Carl Tubbs, MD
Ophthalmology · Parker, CONPI 1033114335
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,510 of the $5,645 with a category attached, or 62.2%. Glaukos Corporation accounts for 66.7% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2020 at $2,258 and has fallen 77.2% since, to $515 in 2025.
Across 102 payments — averaging $55.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$4K
- Alcon$465
- AbbVie$168
- Tarsus Pharmaceuticals, Inc.$167
- NEW World Medical,inc.$135
- Kala Pharmaceuticals, Inc.$133
- plus $809 from 17 others
Across 52 payments — averaging $994.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$45K
- Glaukos Corporation$7K
What the payments were for
- Consulting fees$3,51062%
- Food & beverage$2,11637%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 11 | $3,768 |
| Alcon | 22 | $465 |
| AbbVie(2 entities) | 11 | $168 |
| Tarsus Pharmaceuticals, Inc. | 6 | $167 |
| NEW World Medical,inc. | 2 | $135 |
| Kala Pharmaceuticals, Inc. | 6 | $133 |
| Akorn, Inc. | 7 | $108 |
| Rxsight Inc | 2 | $102 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $85 |
| Harrow Eye, LLC | 5 | $83 |
| Aerie Pharmaceuticals, Inc. | 3 | $66 |
| Biotissue Holdings Inc. | 5 | $61 |
| Sight Sciences, Inc. | 3 | $53 |
| Iridex Corporation | 2 | $35 |
| Novartis | 2 | $34 |
| Amgen(2 entities) | 2 | $32 |
| Eyevance Pharmaceuticals LLC | 2 | $28 |
| Sun Pharmaceutical Industries Inc. | 2 | $27 |
| Bausch & Lomb Americas Inc. | 1 | $22 |
| Ivantis, Inc | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Oyster Point Pharma, Inc. | 1 | $19 |
| Omeros Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iDoseTR$143
How this compares
$5,645 in reported general payments places this provider in the 80th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 55 | $57,886 |
| LumiganBimatoprost | 72 | $44,544 |
| XiidraLifitegrast | 40 | $41,394 |
| RocklatanNetarsudil Mesylat/Latanoprost | 11 | $7,616 |
| Prednisolone Acetate | 239 | $7,503 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $7,281 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 23 | $6,856 |
| MoxifloxacinMoxifloxacin Hcl | 205 | $4,931 |
| Ketorolac Tromethamine | 207 | $3,375 |
| Cyclosporine | 11 | $3,086 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 147 | $2,880 |
| Latanoprost | 225 | $2,758 |
| Pilocarpine Hcl | 31 | $2,048 |
| Travoprost | 11 | $1,184 |
| Brimonidine Tartrate | 96 | $1,130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $168 | $109,711142 claims |
| Bausch & Lomb Americas Inc.Xiidra | $22 | $41,39440 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $66 | $7,61611 claims |
| AlconSimbrinza | $465 | $6,85623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 262 ophthalmology providers in Colorado.
Other ophthalmology in Parker
- Carl JohnsonParker$7K
- Mark PackerBoulder$3.5M
- Jon DishlerGreenwood Village$1M
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Geeta Lalchandani LalwaniBoulder$319K
- Richard DavidsonAurora$316K
- Steven DeweyColorado Springs$246K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.